Human Bite Infections Medication

  • Author: Don R Revis Jr, MD; Chief Editor: Burke A Cunha, MD   more...
 
Updated: Jan 11, 2012
 

Medication Summary

The question of which patients require antibiotic therapy is a matter of considerable debate. Antibiotics cannot avert or cure infections in the face of poor wound care, reflecting the importance of meticulous treatment of the wound as the cornerstone of therapy. In regard to antibiotic therapy, it is best to err on the side of caution because the risks of antibiotic therapy are minimal, while the potential complications of bite wound infections are considerable.

In general, superficial noninfected wounds involving sites other than the hand that are evaluated early in the compliant patient without significant comorbidities may be treated without antibiotics if the wound is left open to heal by secondary intention.

Wounds of the hand, infected wounds, and wounds of the head and neck closed primarily mandate antibiotic therapy.

Wounds treated on an outpatient basis may be treated with oral antibiotics, whereas wounds requiring admission to the hospital should be treated with intravenous antibiotics.

Prophylaxis in the noninfected wound should be continued for 5-7 days, whereas therapeutic antibiotics should be administered for 10-14 days.

Selection of the appropriate antibiotic involves multiple factors, including culture results if obtained and available, drug sensitivities, patient age, drug interactions, expected compliance, and renal and hepatic function.

Next

Antibiotics

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Amoxicillin and clavulanic acid (Augmentin)

 

Drug combination treats bacteria resistant to beta-lactam antibiotics. The most effective and economical choice for outpatient therapy unless contraindicated.

In children >3 mo, base dosing protocol on amoxicillin content. Because of different amoxicillin/clavulanic acid ratios in 250-mg tab (250/125) vs 250-mg chewable tab (250/62.5), do not use 250-mg tab until child weighs >40 kg.

Doxycycline (Doryx, Vibramycin, Vibra-Tabs)

 

Alternative for oral therapy in the penicillin-allergic patient. Inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Ceftriaxone sodium (Rocephin)

 

Third-generation cephalosporin with broad-spectrum, gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins. Once-daily IM dosing may benefit the noncompliant patient. Also may be used as an IV antibiotic for patients admitted to the hospital.

Cefoxitin sodium (Mefoxin)

 

Second-generation cephalosporin indicated for gram-positive cocci and gram-negative rod infections. Infections caused by cephalosporin- or penicillin-resistant gram-negative bacteria may respond to cefoxitin.

Ampicillin sodium and sulbactam (Unasyn)

 

Drug combination of beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens.

Ticarcillin disodium and clavulanic acid (Timentin)

 

Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Don R Revis Jr, MD  Consulting Staff, Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Florida College of Medicine

Don R Revis Jr, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Society for Aesthetic Plastic Surgery, and American Society of Plastic Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Thomas J Marrie, MD  Dean of Faculty of Medicine, Dalhousie University Faculty of Medicine, Canada

Thomas J Marrie, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society for Microbiology, Canadian Infectious Disease Society, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Ronald A Greenfield, MD  Professor, Department of Internal Medicine, University of Oklahoma College of Medicine

Ronald A Greenfield, MD is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Central Society for Clinical Research, Infectious Diseases Society of America, Medical Mycology Society of the Americas, Phi Beta Kappa, Southern Society for Clinical Investigation, and Southwestern Association of Clinical Microbiology

Disclosure: Pfizer Honoraria Speaking and teaching; Gilead Honoraria Speaking and teaching; Ortho McNeil Honoraria Speaking and teaching; Abbott Honoraria Speaking and teaching; Astellas Honoraria Speaking and teaching; Cubist Honoraria Speaking and teaching; Forest Pharmaceuticals Speaking and teaching

Eleftherios Mylonakis, MD  Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital

Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

References
  1. Khajotia RR, Lee E. Transmission of human immunodeficiency virus through saliva after a lip bite. Arch Intern Med. Sep 8 1997;157(16):1901. [Medline].

  2. Vidmar L, Poljak M, Tomazic J, Seme K, Klavs I. Transmission of HIV-1 by human bite. Lancet. Jun 22 1996;347(9017):1762. [Medline].

  3. Freeman AJ, Senn DR, Arendt DM. Seven hundred seventy eight bite marks: analysis by anatomic location, victim and biter demographics, type of crime, and legal disposition. J Forensic Sci. Nov 2005;50(6):1436-43. [Medline].

  4. Okimura JT, Norton SA. Jealousy and mutilation: nose-biting as retribution for adultery. Lancet. Dec 19-26 1998;352(9145):2010-1. [Medline].

  5. Presutti RJ. Bite wounds. Early treatment and prophylaxis against infectious complications. Postgrad Med. Apr 1997;101(4):243-4, 246-52, 254. [Medline].

  6. Welbury RR, Murphy JM. The dental practitioner's role in protecting children from abuse. 3. Reporting and subsequent management of abuse. Br Dent J. Feb 14 1998;184(3):115-9. [Medline].

  7. Bunzli WF, Wright DH, Hoang AT, Dahms RD, Hass WF, Rotschafer JC. Current management of human bites. Pharmacotherapy. Mar-Apr 1998;18(2):227-34. [Medline].

  8. Chidzonga MM. Human bites of the face. A review of 22 cases. S Afr Med J. Feb 1998;88(2):150-2. [Medline].

  9. Corabianu O, Laredo JD, Woimant F, Haguenau M. Hazards of tongue-biting: Streptococcus oralis bacteraemia and vertebral osteomyelitis following a grand mal seizure. J Neurol. Jan 1998;245(1):47-9. [Medline].

  10. Donkor P, Bankas DO. A study of primary closure of human bite injuries to the face. J Oral Maxillofac Surg. May 1997;55(5):479-81; discussion 481-2. [Medline].

  11. Epstein JB, Scully C. Mammalian bites: risk and management. Am J Dent. Jun 1992;5(3):167-71. [Medline].

  12. Goldstein EJ, Citron DM, Hudspeth M, Hunt Gerardo S, Merriam CV. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother. Jul 1997;41(7):1552-7. [Medline].

  13. Goldstein EJ, Citron DM, Hudspeth M, Hunt Gerardo S, Merriam CV. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. J Antimicrob Chemother. Mar 1998;41(3):391-6. [Medline].

  14. Griego RD, Rosen T, Orengo IF, Wolf JE. Dog, cat, and human bites: a review. J Am Acad Dermatol. Dec 1995;33(6):1019-29. [Medline].

  15. Kelly IP, Cunney RJ, Smyth EG, Colville J. The management of human bite injuries of the hand. Injury. Sep 1996;27(7):481-4. [Medline].

  16. Ruskin JD, Laney TJ, Wendt SV, Markin RS. Treatment of mammalian bite wounds of the maxillofacial region. J Oral Maxillofac Surg. Feb 1993;51(2):174-6. [Medline].

  17. Ulione MS, Dooling M. Preschool injuries in child care centers: nursing strategies for prevention. J Pediatr Health Care. May-Jun 1997;11(3):111-6. [Medline].

  18. [Guideline] University of Texas, School of Nursing, Family Nurse Practitioner Program. Management of human bite wounds. Austin (TX): University of Texas, School of Nursing; 2007 May. 22 p. [41 references].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.